Lyme Disease Vaccine Candidate to enter Phase 3 Study

NewsDesk @bactiman63 Pfizer Inc. and Valneva SE announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. With increasing global rates of Lyme disease, providing a new option for people to help protect themselves [...]

The post Lyme Disease Vaccine Candidate to enter Phase 3 Study appeared first on Outbreak News Today.